Claims for Patent: 10,028,955
✉ Email this page to a colleague
Summary for Patent: 10,028,955
| Title: | FGFR inhibitor for use in the treatment of hypophosphatemic disorders |
| Abstract: | The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-ph- enylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-ph- enylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome. |
| Inventor(s): | Kneissel; Michaela (Basel, CH), Guagnano; Vito (Basel, CH), Graus Porta; Diana (Basel, CH), Wohrle; Simon (Vienna, AT) |
| Assignee: | Novartis AG (Basel, CH) |
| Application Number: | 15/272,633 |
| Patent Claims: | 1. A method of treating a disease selected from the group consisting of post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia and
McCune-Albright syndrome with a therapeutically effective amount of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-ph- enylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt thereof.
2. The method of treatment according to claim 1 further comprising a treatment that lasts at least 8 weeks and the dose is about 1-50 mg of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-ph- enylamino]-pyrimid-4-yl}-1-methyl-urea monophosphoric acid salt. 3. The method according to claim 2 wherein the dose is about 1-25 mg. 4. The method according to claim 1 wherein said 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-ph- enylamino]-pyrimid-4-yl}-1-methyl-urea is in the form of monophosphoric acid salt and is used in combination with another FGFR inhibitor, phosphate, calcium, osteopontin (OPN), parathyroid hormone or its analogue (PTH), vitamin D or vitamin D analogue. 5. The method of claim 1, wherein 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-ph- enylamino]-pyrimid-4-yl}-1-methyl-urea is in the form of monophosphoric acid salt. 6. The method of claim 1, wherein 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-ph- enylamino]-pyrimid-4-yl}-1-methyl-urea is in the form of free base. |
Details for Patent 10,028,955
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.s.a., Inc. | NATPARA | parathyroid hormone | For Injection | 125511 | January 23, 2015 | ⤷ Try for Free | 2032-03-30 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Showing 1 to 1 of 1 entries
